• Anti Reverse Cap Analog: Boosting mRNA Capping Efficiency

  2026-07-23

  Unlock superior translation and stability in synthetic mRNA workflows with Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G. This precision-engineered cap analog empowers researchers to double translational yield, streamline troubleshooting, and achieve robust mRNA performance for therapeutics and advanced cell engineering.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-07-22

  This study systematically characterizes the pharmacokinetic variability and tissue distribution of Corydalis saxicola Bunting total alkaloids in mice with metabolic dysfunction-associated steatohepatitis (MASH) induced by a high-fat, high-cholesterol diet. It demonstrates how pathological status and transporter/enzyme modulation shape systemic and hepatic exposures, informing rational dosing strategies for MASLD/MASH interventions.

• Biotin-XX Tyramide Reagent: Advancing Spatial Proteome Mappi

  2026-07-22

  Explore how membrane-impermeant Biotin-XX Tyramide Reagent is transforming cell surface proteome profiling, with mechanistic insights, benchmarking against emerging proximity labeling strategies, and actionable guidance for translational researchers aiming to resolve tissue complexity with unprecedented specificity and sensitivity.

• Dye Selection Optimizes Tissue Visibility in Small Biopsy Pr

  2026-07-21

  This study systematically evaluated tissue marking dyes to improve detection and preservation of small biopsy samples during pathology processing. The findings show that hematoxylin provides superior visibility with minimal diagnostic interference, while dyes like crystal violet, although commonly used for nuclear staining in cell assays, have distinct roles and limitations in routine histopathology.

• 740 Y-P: Protocol Enhancements for PI 3-Kinase Activator Stu

  2026-07-21

  740 Y-P unlocks precise PI 3-kinase activation for research on vesicular trafficking, apoptosis, and neuronal survival. This guide translates recent mechanistic discoveries into actionable workflows, troubleshooting strategies, and advanced comparative advantages for PI3K/AKT pathway modulation.

• Safe DNA Gel Stain: Mechanistic Advances and Assay Design Im

  2026-07-20

  Explore how Safe DNA Gel Stain enhances DNA and RNA gel stain workflows, grounded in mechanistic insights and cutting-edge biophysical research. This article uniquely connects stain chemistry to practical assay design and synthetic biology applications.

• Baicalein: Applied Protocols for Cancer and Inflammation Res

  2026-07-20

  Baicalein, a potent 12-LOX inhibitor, empowers researchers to dissect cancer cell proliferation and inflammation pathways with precision. This article guides you through advanced protocols, troubleshooting, and comparative advantages, translating recent reference breakthroughs into actionable steps for bench scientists.

• Perifosine (KRX-0401): Optimizing Akt Inhibition Workflows

  2026-07-19

  Perifosine (KRX-0401) is redefining apoptosis and radiosensitization assays by targeting Akt/mTOR with high selectivity. Discover stepwise protocols, troubleshooting solutions, and unique cross-disciplinary innovations for advanced cancer and neuroprotection research.

• A-1331852: Precision BCL-XL Inhibitor for Advanced Apoptosis

  2026-07-18

  A-1331852 enables high-fidelity, selective targeting of BCL-XL, outperforming legacy inhibitors in both sensitivity and cell-type specificity. Its integration into apoptosis and cancer research workflows empowers robust, reproducible results, as underscored by recent glioblastoma breakthroughs.

• DiscoveryProbe Natural Product Library Plus in Drug Screenin

  2026-07-17

  The DiscoveryProbe Natural Product Library Plus is a curated compound library enabling high-throughput and high-content screening of 1,655 diverse, cell-permeable bioactive compounds. This product supports rapid identification of potent inhibitors and activators in complex disease models, validated for quality and purity by NMR and HPLC. It is a benchmark tool for translational drug discovery, particularly in anti-parasitic and signal transduction research.

• CD47 Suppresses Phagocytosis via Vav Dephosphorylation and R

  2026-07-17

  This study clarifies how CD47 inhibits macrophage phagocytosis by blocking Vav phosphorylation, thus suppressing Rac1-mediated actin remodeling. The work provides granular insight into the intersection of inhibitory CD47/SIRPα signaling and cytoskeletal control, with implications for cancer immunotherapy and targeted Rac pathway interventions.

• TPPU (SKU C5414): Enhancing sEH Inhibition in Cell-Based Ass

  2026-07-16

  This article addresses common laboratory challenges in cell viability and inflammation assays, demonstrating how TPPU (SKU C5414) empowers reproducible, high-sensitivity workflows as a potent soluble epoxide hydrolase inhibitor. Through scenario-driven Q&A, we highlight protocol optimization, data interpretation, and product selection strategies, with direct links to TPPU’s validated usage and supporting literature.

• AR Antagonism Enhances Myeloid-Mediated Immunosuppression in

  2026-07-16

  Consiglio et al. reveal that androgen receptor (AR) antagonism, while effective in prostate cancer therapy, can paradoxically enhance tumor progression by increasing the immunosuppressive activity of myeloid cells. Their work highlights the metabolic and functional consequences of AR blockade in the tumor microenvironment, providing critical insights into resistance mechanisms and future therapeutic strategies.

• Rewiring RCC Research: Sunitinib, Ferroptosis, and New Sensi

  2026-07-15

  Explore the evolving landscape of renal cell carcinoma (RCC) research with a deep dive into Sunitinib—a multi-targeted receptor tyrosine kinase inhibitor—and recent breakthroughs in overcoming therapeutic resistance. This article blends mechanistic insight, translational strategy, and practical protocol guidance to empower researchers seeking next-generation solutions. Anchored in the latest evidence on ferroptosis-mediated sensitization and featuring APExBIO’s rigorously validated Sunitinib, we chart a path beyond standard product literature toward visionary experimental design.

• IPA-3: Applied Pak1 Inhibition for Signaling and Disease Res

  2026-07-15

  IPA-3 uniquely enables non-ATP-competitive, selective Pak1 inhibition, powering advanced kinase assays and cell-based studies with high reproducibility. This guide details actionable protocols, troubleshooting strategies, and innovative use-cases, bridging molecular insight to translational research.

445 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page